Summary of American Epilepsy Society Statements and Letters
Make no mistake... Charlotte's Web IS NOT A PRESCRIPTION MEDICATION AND IS NOT ENDORSED BY THE AES.
President of American Epilepsy Society statement on Charlotte's Web oil- "A study by a team from Children's Hospital Colorado that was presented during the AES Annual meeting in December 2014 and has recently been accepted for publication in the journal Epilepsy & Behavior, found that artisanal "high CBD" oils resulted in no significant reduction in seizures in the majority of patients and in those for whom the parents reported improvements, these improvements were not associated with improvement in electroencephalograms (EEGs), the gold standard monitoring test for people with epilepsy.
The anecdotal results of a few families in Colorado, shared in the media, should not be the basis for law making. The rush by states to pass CBD legislation has created an unusual situation where people with epilepsy and their families are demanding access to a highly variable homegrown substance that may or may not be beneficial and the medical and scientific community lacks the necessary efficacy and safety data to make good treatment decisions regarding cannabis for people with epilepsy, especially in children.."
2016 3 11 Letter to PA Legislator
American Epilepsy Society Letter to Gov. Otter, Idaho
Dr. Wechsler, Medical Director Idaho Comprehensive Epilepsy Center
Details of 3 studies Artisanal CBD--Dr. Chapman and colleagues at Colorado Children’s Hospital and the University of Colorado reviewed cases of 58 children with severe epilepsy who came into their care while using artisanal CBD. Parents reported seizure reduction of 50% or more in only one-third of patients, but except for two children there was no improvement in their EEGs. Adverse effects occurred in 47% of patients: 21% experienced increased or new seizures; 10% suffered developmental regression with one patient needing intubation; one patient died.
CURRENT Articles Charlotte's Web
ICE Epilepsy Alliance Studies
The leader in epilepsy cannabinoid medicine research - GW Pharmaceuticals. On-going studies exist in the United States. The Group's lead program is the development of a product portfolio of cannabinoid prescription medicines to meet patient needs specifically for multiple sclerosis and epilepsy. Excellent article on seizures, GW, & Epidiolex.
What is Charlotte's Web? Charlotte's Web is a strain of marijuana processed into an extract that is high in cannabidiol (CBD) content, called Realm Oil and Alepsia. It does not induce the psychoactive "high" typically associated with recreational marijuana use. For more information
Questions that must be answered before allowing this plant to be called medicine:
What dosage or potency is most beneficial? How often should these children receive this drug? What specific chemical in the marijuana plant is helping reduce seizures? The typical marijuana plant has over 400 chemicals excluding potential pesticides or fertilizers. What medications are these children taking that may be interacting with the marijuana (possibly the real source of help or cause of more issues)? Are these children actually being over-medicated? Is there a difference between how the drug effects boys and girls? Most importantly, given that marijuana or any mood altering drug adversely affects a developing brain, what are the long-term effects? Why don’t these families seek professional medical help in the GW Pharmaceutical study? How many children have this syndrome? How many children in Florida are projected to need and want to experiment with this drug?
Other questions/concerns to consider:
This should not be a political issue. The issue should be about the health and safety of the people who live in our state. Growing pot or allowing marijuana in our state not only circumvents the FDA process for medication but will lead to devastating outcomes throughout our communities. The statistics are slowly being compiled from other states that have legalized marijuana for medical purposes: increased addiction, increase in child and adolescent usage, increase in fatal vehicle accidents, decrease in productivity, increase in absenteeism, and increase in drop-out rates. Any and all money collected from taxes will not even begin to cover the increased expenses of the above tragedies, business and academic issues.3
Report on Parent Survey- PubMed (Please note this is a parent report and not scientific or medical data which the medical associations, foundations and organizations are supporting more research and studies to help determine many of the unanswered and safety concerns when using pot as medicine.
Severe childhood epilepsies are characterized by frequent seizures, neurodevelopmental delays, and impaired quality of life. In these treatment-resistant epilepsies, families often seek alternative treatments. This survey explored the use of cannabidiol-enriched cannabis in children with treatment-resistant epilepsy. The survey was presented to parents belonging to a Facebook group dedicated to sharing information about the use of cannabidiol-enriched cannabis to treat their child's seizures. Nineteen responses met the following inclusion criteria for the study: a diagnosis of epilepsy and current use of cannabidiol-enriched cannabis. Thirteen children had Dravet syndrome, four had Doose syndrome, and one each had Lennox-Gastaut syndrome and idiopathic epilepsy. The average number of antiepileptic drugs (AEDs) tried before using cannabidiol-enriched cannabis was 12. Sixteen (84%) of the 19 parents reported a reduction in their child's seizure frequency while taking cannabidiol-enriched cannabis. Of these, two (11%) reported complete seizure freedom, eight (42%) reported a greater than 80% reduction in seizure frequency, and six (32%) reported a 25-60% seizure reduction. Other beneficial effects included increased alertness, better mood, and improved sleep. Side effects included drowsiness and fatigue. Our survey shows that parents are using cannabidiol-enriched cannabis as a treatment for their children with treatment-resistant epilepsy. Because of the increasing number of states that allow access to medical cannabis, its use will likely be a growing concern for the epilepsy community. Safety and tolerability data for cannabidiol-enriched cannabis use among children are not available. Objective measurements of a standardized preparation of pure cannabidiol are needed to determine whether it is safe, well tolerated, and efficacious at controlling seizures in this pediatric population with difficult-to-treat seizures.
Don’t forget about the many parents who have visited the capital when the Prescription Epidemic was at its pinnacle. We should focus on ending this epidemic - not adding to it.
Does this look like medicine?